These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 16093437)

  • 1. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody.
    Wang Y; Hailey J; Williams D; Wang Y; Lipari P; Malkowski M; Wang X; Xie L; Li G; Saha D; Ling WL; Cannon-Carlson S; Greenberg R; Ramos RA; Shields R; Presta L; Brams P; Bishop WR; Pachter JA
    Mol Cancer Ther; 2005 Aug; 4(8):1214-21. PubMed ID: 16093437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
    Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
    Ji QS; Mulvihill MJ; Rosenfeld-Franklin M; Cooke A; Feng L; Mak G; O'Connor M; Yao Y; Pirritt C; Buck E; Eyzaguirre A; Arnold LD; Gibson NW; Pachter JA
    Mol Cancer Ther; 2007 Aug; 6(8):2158-67. PubMed ID: 17671083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake.
    Shang Y; Mao Y; Batson J; Scales SJ; Phillips G; Lackner MR; Totpal K; Williams S; Yang J; Tang Z; Modrusan Z; Tan C; Liang WC; Tsai SP; Vanderbilt A; Kozuka K; Hoeflich K; Tien J; Ross S; Li C; Lee SH; Song A; Wu Y; Stephan JP; Ashkenazi A; Zha J
    Mol Cancer Ther; 2008 Sep; 7(9):2599-608. PubMed ID: 18790743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin.
    Friedbichler K; Hofmann MH; Kroez M; Ostermann E; Lamche HR; Koessl C; Borges E; Pollak MN; Adolf G; Adam PJ
    Mol Cancer Ther; 2014 Feb; 13(2):399-409. PubMed ID: 24296829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
    Wu JD; Odman A; Higgins LM; Haugk K; Vessella R; Ludwig DL; Plymate SR
    Clin Cancer Res; 2005 Apr; 11(8):3065-74. PubMed ID: 15837762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
    Warshamana-Greene GS; Litz J; Buchdunger E; Hofmann F; García-Echeverría C; Krystal GW
    Mol Cancer Ther; 2004 May; 3(5):527-35. PubMed ID: 15141010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
    Shi Y; Yan H; Frost P; Gera J; Lichtenstein A
    Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased insulin sensitivity in IGF-I receptor--deficient brown adipocytes.
    Mur C; Valverde AM; Kahn CR; Benito M
    Diabetes; 2002 Mar; 51(3):743-54. PubMed ID: 11872675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells.
    Guvakova MA; Surmacz E
    Cancer Res; 1997 Jul; 57(13):2606-10. PubMed ID: 9205064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor-I-dependent signal transduction pathways leading to the induction of cell growth and differentiation of human neuroblastoma cell line SH-SY5Y: the roles of MAP kinase pathway and PI 3-kinase pathway.
    Kurihara S; Hakuno F; Takahashi S
    Endocr J; 2000 Dec; 47(6):739-51. PubMed ID: 11228049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the insulin-like growth factor 1 signaling pathway by the antiapoptotic agents aurintricarboxylic acid and evans blue.
    Beery R; Haimsohn M; Wertheim N; Hemi R; Nir U; Karasik A; Kanety H; Geier A
    Endocrinology; 2001 Jul; 142(7):3098-107. PubMed ID: 11416032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscarinic-receptor-mediated inhibition of insulin-like growth factor-1 receptor-stimulated phosphoinositide 3-kinase signalling in 1321N1 astrocytoma cells.
    Batty IH; Fleming IN; Downes CP
    Biochem J; 2004 May; 379(Pt 3):641-51. PubMed ID: 14769130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoic acid-induced growth arrest of MCF-7 cells involves the selective regulation of the IRS-1/PI 3-kinase/AKT pathway.
    del Rincón SV; Rousseau C; Samanta R; Miller WH
    Oncogene; 2003 May; 22(22):3353-60. PubMed ID: 12776186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine residues in the C-terminal domain of the insulin-like growth factor-I receptor mediate mitogenic and tumorigenic signals.
    Esposito DL; Blakesley VA; Koval AP; Scrimgeour AG; LeRoith D
    Endocrinology; 1997 Jul; 138(7):2979-88. PubMed ID: 9202243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential role of insulin-like growth factor I receptor in insulin-induced fetal brown adipocyte differentiation.
    Mur C; Arribas M; Benito M; Valverde AM
    Endocrinology; 2003 Feb; 144(2):581-93. PubMed ID: 12538620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
    Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS
    Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.